M&A Deal Summary

Alcon Acquires Aerie

On August 22, 2022, Alcon acquired life science company Aerie for 770M USD

Acquisition Highlights
  • This is Alcon’s 3rd transaction in the Life Science sector.
  • This is Alcon’s largest (disclosed) transaction.
  • This is Alcon’s 9th transaction in the United States.
  • This is Alcon’s 1st transaction in North Carolina.

M&A Deal Summary
Date 2022-08-22
Target Aerie
Sector Life Science
Buyer(s) Alcon
Deal Type Add-on Acquisition
Deal Value 770M USD
Advisor(s) Goldman Sachs (Financial)
Fried Frank Harris Shriver & Jacobson LLP (Legal)

Target

Aerie

Durham, North Carolina, United States
website
Aerie is a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies for the treatment of patients with eye diseases and conditions including open-angle glaucoma, dry eye, and diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD). Aerie was founded in 2005 and is based in Durham, North Carolina.

Search 193,448 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Alcon

Fort Worth, Texas, United States

website

Category Company
Founded 1945
Sector Medical Products
DESCRIPTION

Alcon, Inc. is an eye care company that researches, develops, manufactures and markets pharmaceuticals, surgical equipment and devices, contacts lens solutions and other vision care products that treat diseases, disorders and other conditions of the eye. Alcon is located in Fort Worth, Texas and was formed in 1945.

DEAL STATS #
Overall 11 of 11
Sector (Life Science) 3 of 3
Type (Add-on Acquisition) 9 of 9
State (North Carolina) 1 of 1
Country (United States) 9 of 9
Year (2022) 2 of 2
Size (of disclosed) 1 of 4
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-05-23 Kala Pharmaceuticals - EYSUVIS & INVELTYS

Watertown, Massachusetts, United States

Kala Pharmaceuticals' EYSUVIS & INVELTYS provides loteprednol etabonate suspension) 0.25% pharmaceutical eye drops and loteprednol etabonate suspension) 1%, the only corticosteroid for twice-a-day treatment of post-operative inflammation and pain following ocular surgery.

Buy $60M
Mergr

Product

Company

Legal